DelveInsight’s ‘Soft Tissue Sarcoma Market Insights, Epidemiology, and Market Forecast-2030’ report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Soft Tissue Sarcoma (STS) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The Soft Tissue Sarcoma market report provides analysis regarding current treatment practices, emerging drugs like AL3818, Fibromun, AL3818, Ripretinib, market share of the individual therapies, historical, current and forecasted Soft Tissue Sarcoma market Size from 2017 to 2030 segmented by seven major markets.
The Report also covers current Soft Tissue Sarcoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.
“The total Soft Tissue Sarcoma market size, excluding Gastrointestinal stromal tumors (GIST) in seven major markets was USD 246.7 million in 2017.”
Report Highlights:
REQUEST FOR SAMPLE PAGES: https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-market
Table of contents1. Key Insights2. Executive Summary of Soft-Tissue Sarcoma3. Soft-Tissue Sarcomas Market Overview at a Glance4. Soft-Tissue Sarcoma Disease Background and Overview5. Soft-Tissue Sarcoma Epidemiology and Patient Population6. Case Reports7. Country Wise Soft-Tissue Sarcoma Epidemiology7.1. United States Epidemiology7.2. EU5 Epidemiology7.2.1. Germany7.2.2. France7.2.3. Italy7.2.4. Spain7.2.5. United Kingdom7.3. Japan Epidemiology8. Soft-Tissue Sarcoma Treatment and Management9. Unmet Needs10. Soft-Tissue Sarcoma Marketed Drugs10.1. Halaven (Eribulin Mesylate): Eisai10.2. Gleevec (Imatinib Mesylate): Novartis10.3. Yondelis (Trabectedin): Pharma Mar10.4. Lartruvo (Olaratumab): Eli Lilly10.5. Vitrakvi (Larotrectinib; BAY2757556): Bayer/Loxo Oncology10.6. Stivarga (Regorafenib): Bayer10.7. Sutent (Sunitinib malate): Pfizer10.8. Votrient (Pazopanib): GlaxoSmithKline/Novartis10.9. Vincristine Sulfate: Hospira10.10. Rozlytrek (Entrectinib): Roche (Genentech)11. Soft-Tissue Sarcoma Emerging Drugs11.1. Key Cross Competition- Phase III Emerging Molecules11.2. Avapritinib (BLU-285): Blueprint Medicines Corporation11.3. Vigil (In combination with irinotecan and temozolomide): Gradalis11.4. Anlotinib (AL3818): Advenchen Laboratories/Jiangsu Chia-Tai Tianqing Pharmaceutical11.5. Selinexor: Karyopharm Therapeutics11.6. Aldoxorubicin (INNO-206): CytRx11.7. Ripretinib (DCC-2618): Deciphera Pharmaceuticals11.8. Fibromun (In combination with Doxorubicin): Philogen11.9. Hensify (NBTXR3): Nanobiotix11.10. Crenolanib: Arog Pharmaceuticals11.11. TAS-116: Taiho Pharmaceutical11.12. GSK3377794: GlaxoSmithKline/ Adaptimmune11.13. ADP-A2M4: Adaptimmune12. Soft Tissue Sarcoma 7 Major Market Analysis13. Market Outlook: The United States13.1. United States Market Size14. Market Outlook: Europe14.1. Germany14.2. France14.3. Italy14.4. Spain14.5. United Kingdom15. Soft-Tissue Sarcoma Market Outlook: Japan16. Access and Reimbursement Overview of Soft-Tissue Sarcoma17. Market Drivers18. Market Barriers19. SWOT Analysis20. Appendix21. DelveInsight Capabilities22. Disclaimer23. About DelveInsight
About DelveInsightDelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/